New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:07 EDTOMEROmeros price target lowered to $16 from $19 at Burrill
Burrill lowered its price target for Omeros after the company announced that OMS103HP did not meet its primary endpoint in patients undergoing arthroscopic partial meniscectomy surgery. The firm notes that OMS103HP achieved statistically significant reduction of postoperative pain, though, and keeps an Outperform rating on the stock.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:16 EDTOMEROn The Fly: Pre-market Movers
Subscribe for More Information
07:02 EDTOMEROmeros reports OMS721 inhibits thrombus formation in sera from aHUS patients
Subscribe for More Information
November 13, 2014
08:16 EDTOMEROmeros price target raised to $28 from $20 at Maxim
Maxim raised its price target for Omeros shares to $28 citing better than expected pricing for Omidria. The firm believes global sales of the drug could reach north of $400M by 2017 and keeps a Buy rating on Omeros.
November 10, 2014
16:12 EDTOMEROmeros reports Q3 EPS (54c), consensus (59c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use